OEM Contract Development Manufacturing Organization Manufacturers & Supplier

Conventional herbal extract suppliers operate purely as commodity ingredient distributors with minimal analytical standardization beyond non-specific UV spectrophotometry. MedGence functions as an integrated scientific research organization (CRO) and contract development manufacturing organization (CDMO). We own our pilot plants and direct collaborative cGMP manufacturing sites. We don't merely extract botanicals; we identify active biomarkers, optimize multi-origin sourcing matrices, establish validated HPLC/HPTLC/GC-MS fingerprint standards, perform preclinical in vitro and animal pharmacological tests, and manage Phase I–IV clinical trials. This ensures that the botanical API you commercialize possesses molecular continuity, clinical efficacy validation, and robust regulatory defense.

Botanical chemotypes naturally oscillate due to soil chemistry, altitude, solar radiation, and rainfall. To guarantee batch-to-batch consistency for pharmaceutical commercialization, we conduct origin and seasonal potency evaluations across multiple geographic quadrants. By establishing chromatographic fingerprinting baselines and minimum biomarker thresholds, we formulate precise blending ratios of qualified botanical batches prior to extraction. Furthermore, our Process Analytical Technology (PAT) continuously measures active marker concentrations in real-time, allowing operators to adjust extraction duration, temperature, and solvent ratios dynamically to achieve the exact target concentration specified in your Certificate of Analysis.

At the active ingredient level, we deliver high-purity spray-dried powders, vacuum-dried crystal extracts, dense liquid pastes, supercritical CO2 volatile oils, and standardized aqueous concentrates. For commercial finished products, our Class D cGMP facilities provide end-to-end formulation and packaging for: oral liquids and syrups, two-piece hard gelatin and vegetable (HPMC) capsules, softgels with lipid carrier matrices, enteric-coated or direct-compression tablets, soluble effervescent granules, and micro-encapsulated sachets.

We operate under an entrusted contract model where the client retains 100% intellectual property ownership of the proprietary formulas, process refinements, and study deliverables generated. Legally binding Non-Disclosure and Non-Compete Agreements (NDAs) are executed prior to data transfer. In our production facilities, batch records use coded identifiers rather than brand names to ensure operational technicians have no visibility into the commercial client identity. Data logs are hosted on isolated, encrypted internal networks, guaranteeing your competitive advantage remains intact throughout the product lifecycle.

Yes. Developing botanical drugs under the US FDA Botanical Drug Guidance (2016) or EMA Herbal Medicinal regulations requires exceptional Chemistry, Manufacturing, and Controls (CMC) rigor. Having modernized 83 classic formulations and registered 22 innovative natural medicines, our scientific team generates the comprehensive data sets required by regulatory bodies: multi-batch raw material consistency data, chromatographic fingerprints, in vitro mode-of-action bioassays, GLP toxicity studies (acute, chronic, genotoxicity, reproductive tox), and GCP Phase I–IV clinical dossiers.

For initial phytochemical screening and analytical method development, typical timelines range from 4 to 8 weeks. Pilot extraction batch validation (50kg to 200kg crude herb input) requires approximately 6 to 10 weeks, culminating in a comprehensive technical transfer report. For commercial OEM/CDMO production, MOQs depend on the finished dosage form (e.g., 500kg for active extract powders; 300,000 to 500,000 units for capsules/tablets). Turnaround time for recurring commercial batch manufacturing averages 4 to 6 weeks from raw material intake clearance.